Ivabradina Bluepharma (Ivabradine Hydrochloride)

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node. This slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate while preserving myocardial contractility and blood pressure, thereby reducing cardiac oxygen demand.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart rate, clinical condition and concomitant therapies. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety of ivabradine during pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively blocking the If current without affecting beta‑adrenergic receptors. This can be advantageous in patients who cannot tolerate beta‑blockers or need additional heart‑rate reduction beyond what beta‑blockers provide.

Ivabradina Bluepharma tablets should be stored at room temperature, below 25 °C, in the original blister pack. Keep the product away from moisture and direct sunlight to maintain stability.

The medication is taken orally, usually with a glass of water. Tablets should be swallowed whole and not crushed or chewed. Dosing times are typically aligned with the prescriber’s instructions, often twice daily with meals.

Serious adverse events include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to persistent vision loss. Patients should be monitored for these signs, and therapy should be discontinued if they occur.

Ivabradine is contraindicated in patients with sick sinus syndrome, sinoatrial block, resting heart rate below 60 bpm, severe hepatic impairment, or those taking strong CYP3A4 inhibitors. It should also be used with caution in patients with renal dysfunction.